SOCS3 (D6E1T) Rabbit Monoclonal Antibody #52113
- WB
Product Specifications
| REACTIVITY | H M |
| SENSITIVITY | Endogenous |
| MW (kDa) | 28 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
实验步骤
Specificity / Sensitivity
Species Reactivity:
Source / Purification
Background
Low levels of SOCS3 are observed in lung, spleen, and thymus and, like other SOCS family members, its expression is rapidly induced by a number of factors including interleukins, EPO, IFN-γ, CSF, and TNF-α (4). SOCS3 uses its SH2 domain to bind activated Jaks and their cognate receptors to provide negative feedback inhibition. In addition to the initially described inducers of SOCS3 expression, subsequent studies have described SOCS3-mediated negative feedback inhibition for leptin (5), GH (6), chemokine receptors (7), insulin (8), and certain pathogens (9,10). SOCS3 deletion results in embryonic lethality with placental insufficiency (11). SOCS3 signaling has been linked pathologically to allergic responses (12), inflammatory disease (13), endotoxic shock (14), wound repair (15), and obesity (16,17).
- Alexander, W.S. et al. (1999) J Leukoc Biol 66, 588-92.
- Chen, X.P. et al. (2000) Immunity 13, 287-90.
- Hilton, D.J. et al. (1998) Proc Natl Acad Sci USA 95, 114-9.
- Starr, R. et al. (1997) Nature 387, 917-21.
- Bjørbaek, C. et al. (1998) Mol Cell 1, 619-25.
- Adams, T.E. et al. (1998) J Biol Chem 273, 1285-7.
- Soriano, S.F. et al. (2002) J Exp Med 196, 311-21.
- Emanuelli, B. et al. (2000) J Biol Chem 275, 15985-91.
- Stoiber, D. et al. (1999) J Immunol 163, 2640-7.
- Stoiber, D. et al. (2001) J Immunol 166, 466-72.
- Roberts, A.W. et al. (2001) Proc Natl Acad Sci U S A 98, 9324-9.
- Seki, Y. et al. (2003) Nat Med 9, 1047-54.
- Shouda, T. et al. (2001) J Clin Invest 108, 1781-8.
- Fang, M. et al. (2005) Cell Mol Immunol 2, 373-7.
- Goren, I. et al. (2006) J Invest Dermatol 126, 477-85.
- Mori, H. et al. (2004) Nat Med 10, 739-43.
- Howard, J.K. et al. (2004) Nat Med 10, 734-8.
Alternate Names
ATOD4; CIS-3; CIS3; Cish3; cytokine-induced SH2 protein 3; Cytokine-inducible SH2 protein 3; MGC71791; SOCS-3; SOCS3; SSI-3; SSI3; STAT-induced STAT inhibitor 3; Suppressor of cytokine signaling 3
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专